Sign in Subscribe
Cancer research

Research Uncovers Risk of Ischemic Stroke in Cancer Patients with Venous Thromboembolism

Strategic Insights

— 1 min read

Recent research has shed light on the increased risk of ischemic stroke in cancer patients who develop venous thromboembolism (VTE). A study published in Blood Advances observed that patients treated with direct oral anticoagulants (DOACs) had a higher cumulative incidence of ischemic stroke compared to those treated with low-molecular-weight heparin (LWMH) or warfarin. The study aimed to determine the impact of different anticoagulant classes on the risk of ischemic stroke in patients with cancer-associated VTE.

Key Takeaways:

  • The study found that the cumulative incidence of ischemic stroke was 5.6% overall at 6-months, with 6.8% in DOAC, 4.9% in LMWH, and 5.2% in warfarin treatment groups (p = 0.040).
  • Hypertension (OR 1.75), atrial fibrillation/flutter (OR 1.37), DOAC use (OR 1.36), and prior stroke (OR 3.59) were identified as statistically significant risk factors for ischemic stroke.
  • The study suggests that ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.
  • The research highlights the need for caution when using DOACs in patients with cancer-associated VTE and the importance of monitoring for risk factors such as hypertension and prior stroke.

Statistics:

  • 4,875 total patients were included in the study, with 1,625 patients in each treatment group (DOAC, LMWH, and warfarin).
  • The cumulative incidence of ischemic stroke was 5.6% overall at 6-months, with 6.8%, 4.9%, and 5.2% in DOAC, LMWH, and warfarin treatment groups, respectively.
  • Hypertension was a significant risk factor for ischemic stroke, with an odds ratio of 1.75.
  • Prior stroke was also a significant risk factor, with an odds ratio of 3.59.

Sources:

  • Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism (2025)
  • Blood Advances (published by Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands)
  • Yu-Cheng Chang, Danbury Hospital, Danbury, Connecticut, United States (author contact)

Read more